IperionX (ASX:IPX) Losses Hit US$34m, The Onshoring Bet Gets Pricier

Admin Costs Up 5x, Now Prove the Titanium Scale Up

IperionX fell 7% to US$6.50 after releasing its half-year result. The stock has had a volatile year, reaching highs of US$8 before short reports triggered concerns around the growth story.

IperionX remains pre-revenue, but the broader story still aligns with the US push to onshore titanium manufacturing and processing. That is why the company has become a serious contender for US funding, including the US$47M it has received from the Department of Defense. The challenge is that this comes with a highly capital-intensive business model, and investors are becoming more cautious as losses continue to rise.

Net losses doubled over the year to US$34M. That is a big jump, but it reflects a company deliberately spending to build out infrastructure, manufacturing capability, and government contract execution.

The biggest increase came through corporate and administrative costs, which rose from US$3.3M to US$16.2M, nearly a fivefold increase. Management pointed to higher salary and overhead costs, as well as the implementation of a new enterprise resource planning system.

For us, this does not look like a deterioration in the business. IperionX is reinvesting heavily for future growth. The issue is that this raises financing risk, because the facilities and contracts now need to deliver returns. The key question is not whether the loss is large, but whether the capital being deployed today will create meaningful shareholder value over time.

What are the Best ASX Stocks to invest in right now?

Check our buy/sell tips

US$65m Cash, Roughly 12 Months of Runway, Still Pre Revenue

Property, plant and equipment increased by US$10M, while the cash balance rose to US$65M. That cash build was fully equity funded, with the company raising around US$70M through a share placement. The increase in PPE reflects the start of the 1,400tpa capacity expansion, which is backed by the DoD. Importantly, the government is covering a meaningful portion of this through cost-reimbursement contracts, so the actual cash burden on IperionX is much lower than the headline capex number suggests.

Government support has also helped on the feedstock side. The US government transferred 290 metric tonnes of Ti64 alloy scrap to IperionX at no cost, which is enough to cover roughly 1.5 years of feedstock at full 200tpa capacity. At market prices, that material is worth several million dollars and materially reduces near-term input cost pressure.

If we look at the broader funding pathway, the support could become much larger over time. The DPA has already awarded US$12.7M, while IperionX has also received US$47.1M in funding, with Phase 3 creating the potential for around US$100M more in future support. That gives the company a much stronger funding runway as it scales.

On the manufacturing side, current powder production capacity stands at 200 metric tonnes per year at the Virginia Titanium Manufacturing Campus. That represents a 60x increase from pilot scale. From here, the company is moving into the next phase of expansion, with cold isostatic presses and sintering furnaces ordered as it works toward its 2027 target of 1,400tpa.

Execution Clock Starts

The key takeaway for investors is that while IperionX is receiving strong support from both the government and equity markets, and the long-term growth story could still deliver meaningful upside, invested capital is rising quickly and the cost base is increasing sharply.

Corporate and administrative costs have nearly increased 5x year over year. While part of that was affected by a one-off legal settlement, the underlying cost run-rate has still moved structurally higher.

The company appears to have roughly a year of funding at the current burn rate, while revenue remains close to zero. Prototype orders are still at the seed stage, and there is little visibility yet on the timing of larger volume contracts.

That means this is a much more speculative investment. The upside could be significant if the company executes, but at this stage the story still depends heavily on future contract wins, scaling success, and continued funding support.